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Objectives: Statins are lipid-lowering drugs with anti-inflammatory and antioxidant
properties. This study explores the potential of these commonly prescribed agents to
ameliorate lung ischemia-reperfusion injury.
Methods: Left lungs of Long-Evans rats were rendered ischemic for 90 minutes and
reperfused for up to 4 hours. Treated animals received simvastatin orally (0.5
mg/kg) for 5 days before the experiment. Injury was quantitated in terms of tissue
myeloperoxidase content, vascular permeability (125I bovine serum albumin extrav-
asation), and bronchoalveolar lavage leukocyte and cytokine content. Changes in
nuclear translocation of transcription factors were evaluated by electromobility shift
assay. Additional animals received NG-nitro-L-arginine methyl ester before isch-
emia-reperfusion to assess whether inhibition of nitric oxide synthase could reverse
simvastatin’s protective effects. The presence of nicotinamide adenine dinucleotide
phosphate oxidase was also evaluated using enzyme staining both histologically and
in native electrophoresis.
Results: Lung vascular permeability was reduced in treated animals by 71% com-
pared with positive controls (P  .001). Administration of NG-nitro-L-arginine
methyl ester reversed this protection. The protective effects of statin pretreatment
correlated with a 68% reduction in tissue myeloperoxidase content (P  .01),
marked reductions in bronchoalveolar lavage leukocyte accumulation, and de-
creased expression of proinflammatory cytokines. Nicotinamide adenine dinucle-
otide phosphate oxidase expression also decreased with statin treatment.
Conclusion: In addition to its antioxidant properties, the protective effects of
simvastatin are likely mediated by modulation of endothelial nitric oxide synthase.
The potential to pretreat recipients of lung transplantation with statins to ameliorate
reperfusion injury is promising.
Statins are a class of compounds that competitively inhibit the enzyme3-hydroxy-3-methylglutaryl coenzyme A reductase, the first commit-ted step in cholesterol biosynthesis. Increasingly, the pleiotropic prop-erties of statins are being described. In endothelial cells, all of theseeffects seem to result from the inhibition of cholesterol’s precursormevalonic acid, which is critical to the isoprenylation of a diverse
family of proteins.1 Posttranslational prenylation of these proteins is a prerequisite
for membrane association and function. Members of this family are involved in cell
signaling, differentiation and proliferation, myelination, cellular transport, and cy-
toskeletal function.2
The protective effects of statins have been described in models of renal, cerebral,
and cardiac reperfusion injury,3-5 as well as in remote lung injury that develops after
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hind-limb ischemia.6 In these models, the mechanism me-
diating this protection is not fully elaborated. Reperfusion is
associated with a posttranscriptional reduction in the ex-
pression of the enzyme endothelial nitric oxide synthase
(eNOS). Preservation of NO production in the reperfusion
period seen with statin treatment is believed to protect
against postischemic vasoconstriction directly,7 and may
also do so indirectly by altering endothelin-1 activity.8
Furthermore, NO may inhibit neutrophil-endothelial inter-
actions resulting in reduced neutrophil recruitment and tis-
sue injury. In a model of cerebral reperfusion injury, the
protective effects of statin pretreatment were lost in eNOS
knockout mice.9
After lung transplantation and pulmonary thromboendar-
terectomy, lung ischemia-reperfusion injury (LIRI) is asso-
ciated with an increase in vascular permeability and mani-
fests itself clinically as pulmonary edema.10 In animal
models, this vascular injury is biphasic.11 The late phase is
dependent on neutrophil recruitment, whereas the early
stage is independent of it, occurring within 15 minutes of
reperfusion. It is during this early stage that an initial burst
of free radical production occurs, believed to be secondary
to increased nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase activity in alveolar macrophages. Statins
have been shown to inhibit NADPH oxidase in vitro result-
ing in decreased reactive oxygen intermediate (ROI) pro-
duction.12,13
Knowing that statins have anti-inflammatory and antiox-
idant properties, and are protective in other models of reper-
fusion injury, we hypothesized that statin pretreatment
would be protective against direct LIRI. This protection is
likely mediated by modulated expression of NOS and
NADPH oxidase.
Materials and Methods
Reagents
All reagents were purchased from Sigma Chemical Company (St
Louis, Mo) unless otherwise specified.
Animal Model
Pathogen-free adult male Long-Evans rats (Simonsen Labs, Gil-
roy, Calif), weighing 280 to 320 g, were used for all experiments.
All animals received humane care in compliance with the Guide-
lines for Care and Use of Laboratory Animals, published by the
National Society for Medical Research and the National Institutes
of Health. An in situ warm ischemia model was used as described
previously.14 Treated animals received simvastatin 0.5 mg/kg per
day by oral gavage for 5 days before undergoing any experimental
procedure. In brief, anesthesia was induced with pentobarbital, and
animals were ventilated by tracheostomy (Harvard Rodent Venti-
lator, Harvard Apparatus Inc, Holliston, Mass). All animals re-
ceived 0.2 mg of atropine intramuscularly and 50 units of intra-
venous heparin. Anesthesia was maintained with inhaled
halothane. The left lung was mobilized atraumatically through an
anterolateral thoracotomy and the left pulmonary artery, veins, and
main stem bronchus were occluded with a noncrushing microvas-
cular clamp. At the end of the 90-minute ischemic period, the
clamp was removed, and the lung was ventilated and reperfused
for periods of up to 4 hours. At the conclusion of the reperfusion
period, blood samples were obtained from the inferior vena cava,
the heart lung block was rapidly excised, and the pulmonary
circulation was flushed with 20 mL of normal saline solution
through the main pulmonary artery.
Lung Permeability Index
To quantitate lung injury, a permeability index (PI) was deter-
mined as described previously.11,14 125I-radiolabeled bovine serum
albumin (NEN Life Sciences, Boston, Mass), titrated to an activity
of 800,000 counts/min per dose, was intravenously injected in a
final volume of 1 mL of 1% bovine serum albumin phosphate-
buffered saline solution 5 minutes before removal of the hilar
clamp. At the end of the experiment, the radioactivity counts were
quantitated in the left lung and in 1 mL of inferior vena cava blood
using a scintillation counter. The PI was then calculated as follows:
Permeability index
Left lung (cpm)
1.0 mL blood (cpm)
This ratio corrected for any variation in systemic blood levels
of radioactivity and provided a reproducible measure of lung
microvascular permeability.
Treatment with NG-Nitro-L-Arginine Methyl Ester
Additional groups of animals underwent pretreatment with an
eNOS and inducible NOS (iNOS) inhibitor NG-nitro-L-arginine
methyl ester (L-NAME) before undergoing ischemia-reperfusion
as described previously. L-NAME was delivered 30 minutes before
ischemia as a 300-L intratracheal injection at a concentration of
5 mmol/L. This dose was used because it was shown to be
protective in a rat model of immune complex-induced vasculitis.15
Four groups were compared in this experiment, and all underwent
ischemia of 90 minutes and reperfusion of 4 hours. The groups
consisted of the following: animals receiving L-NAME only, ani-
mals receiving statin only, animals not receiving any drugs, and
animals receiving statin followed by L-NAME.
Myeloperoxidase Assay
Tissue myeloperoxidase (MPO) assay content was used to quan-
titate neutrophil accumulation in the lungs as described previous-
ly.14 Lung samples were homogenized in a phosphate buffer
containing 0.5% hexadecyltrimethylammonium bromide. Samples
were then assayed for the ability to decompose H2O2 in the
presence of O-dianisidine dihydrochloride by the change in ab-
sorption at 460 nm during 1 minute.
Bronchoalveolar Lavage
Additional animals underwent bronchoalveolar lavage (BAL) at
the time of death. Through the tracheostomy, lungs were lavaged
individually by clamping the contralateral hilum and instilling 3.0
mL of saline solution that was flushed and aspirated 3 times. This
fluid was centrifuged (1500g  8 minutes at 4°C) to pellet the
cells, and the supernatant was snap-frozen for subsequent cytokine
analysis after the addition of a protease cocktail inhibitor (leupep-
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tin 1 g/mL, aprotinin 1 g/mL, trypsin inhibitor 5 g/mL, and
pepstatin A 1 g/mL). The red blood cells were lysed, and the
pellet was resuspended in normal saline solution. Total nucleated
cells were counted using a hemacytometer (Hausser Scientific,
Reading, Pa).
Enzyme-Linked Immunosorbent Assay
A standard sandwich enzyme-linked immunosorbent assay proto-
col was used to evaluate the elaboration of tumor necrosis factor
(TNF)-. The capture antibody was a monoclonal anti-rat TNF-
(R&D Systems, Minneapolis, Minn) plated at a concentration of
2.5 g/mL. The detection antibody was a biotinylated polyclonal
anti-rat TNF- (R&D Systems) at 0.25 g/mL. A streptavidin
conjugate was used at a 1:1000 dilution (Zymed, San Francisco,
Calif), and the detection was quantitated with Sigma Fast o-
phenylenediamine (OPD).
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assays were performed as previously
described14 using 32P end-labeled oligonucleotides specific for the
consensus binding sequence of nuclear factor-B (NF-B) and
activator protein-1 (AP-1; Promega, Madison, Wis).
Western Blot Analysis for eNOS and iNOS
Antibodies for eNOS and iNOS (Signal Transduction Laborato-
ries, Lexington, Ky) were used at 1:500 dilutions. Expression of
eNOS and iNOS in cytosolic protein samples was assessed by
Western blot analysis. Membranes were developed using standard
horseradish peroxidase and avidin biotin complex methods.
Enzymatic Localization and Characterization of
NADPH Oxidase
NADPH diaphorase is a histochemical stain14 that uses exoge-
nous-reduced NADPH as a substrate and the chromophore ni-
troblue tetrazolium as a redox indicator. Frozen sections of optimal
cutting temperature-filled lungs were incubated with a Tris HCl
buffer containing nitroblue tetrazolium (1 mg/mL) and -NADPH
(0.4 mg/mL) in a humidified chamber for 1 hour at 37°C. Sections
were dehydrated, mounted, and examined by light microscopy.
Enzyme Electrophoresis
Nondenaturing 6.0% polyacrylamide gels were cast containing 1.5
mmol/L Tris, pH 8.8, acrylamide, TEMED, and ammonium per-
sulfate. The separating gel was overlaid with water-saturated bu-
tanol and allowed to polymerize for 1 hour. A 4% stacking gel was
cast containing 0.5 mmol/L Tris pH 6.8, acrylamide, TEMED, and
ammonium persulfate. Samples were mixed with native sample
buffer consisting of 62.5 mmol/L Tris, pH 6.8, 40% glycerol,
0.01% xylene cyanol FF, and 0.01% bromophenol blue at a ratio
of 1:2. Bio-Rad Laboratories (Hercules, Calif) prestained stan-
dards were loaded (5 L), as was 20 g of cytoplasmic protein.
The gels were then electrophoresed for 4 to 6 hours at 4°C.
Enzyme Staining of Polyacrylamide Gels
The gel was equilibrated in a Tris-HCl buffer pH 7.4 (3.25 g Tris,
1.65 mL concentrated HCl acid, and the volume raised to 500 mL
with distilled water). The gel was then placed in a shallow dish
containing 20 mL of staining solution (Tris-HCl buffer, 20 mg
nitro blue tetrazolium salt, and 8 mg -NADPH). The gel was
incubated for 1 to 2 hours at 37°C with periodic agitation.
Statistical Analysis
All data are presented as mean  SE of the mean. Data sets were
analyzed using Microsoft Excel 97 (Microsoft Corp, Redmond,
Wash) and SPSS version 10 (SPSS Inc, Chicago, Ill). Comparisons
between control groups or between positive controls and treated
animals were performed by the Student t test. Analyses between
more than 2 groups were performed with analysis of variance with
control for multiple comparisons.
Results
Statin Pretreatment Reduces Vascular Permeability
Vascular permeability was assessed at 15 minutes and 4
hours of reperfusion. At 15 minutes of reperfusion, injured
lungs demonstrated an increase in the PI to 0.54  0.07.
This was reduced by 84.5% (0.16  0.02) (P  .008, n 
4) after pretreatment with simvastatin for 5 days (Figure 1).
Figure 1. Vascular permeability. Treatment with simvastatin before ischemia-reperfusion showed a significant
reduction in vascular permeability at 15 minutes (P  .01, n  3) and 4 hours (P < .001, n  3) of reperfusion.
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At 4 hours of reperfusion, the PI increased from 0.09 
0.01 to 0.82  0.022 with injury (P  .001). Statin pre-
treatment reduced lung vascular permeability by 71% (P 
.001, n  3) (Figure 1).
Effect of Statin Pretreatment on Neutrophil
Recruitment
Tissue MPO content increased by 10.7-fold (0.041  0.01-
0.44  0.005, P  .01) and BAL cell count increased by
26-fold (0.8  0.2-21.8  2.1  106 cells, P  .001) in
lungs subjected to 90 minutes of ischemia followed by 4
hours of reperfusion. There was a 64% (0.19  0.04, P 
.002, n  4) (Figure 2, A) reduction in tissue MPO content
and a 71% reduction (6.85  0.56  106 cells P  .001, n
 4) (Figure 2, B) in leukocyte accumulation in the alveolar
space in statin-treated animals.
Effect of Treatment with L-NAME
Permeability indices at 4 hours of reperfusion were com-
pared in animals treated with statin and in animals treated
with statin and L-NAME. L-NAME treatment alone resulted
in a PI similar to that of untreated animals subjected to
ischemia and 4 hours of reperfusion (0.71  0.18 vs 0.75 
0.08 P  NS). Although statin pretreatment produced a
marked decrease in vascular permeability, this was reversed
with administration of L-NAME (n  3) (Figure 3).
Figure 2. Neutrophil recruitment. A, Tissue neutrophil accumulation as measured by myeloperoxidase (MPO)
content was statistically increased at 4 hours of reperfusion when compared with negative controls (P < .001).
These values were markedly decreased in statin-treated animals (P < .002, n  4). B, The bronchoalveolar lavage
(BAL) cell counts increased 26-fold in animals undergoing ischemia-reperfusion when compared with negative
controls (P < .001). A significant decrease in leukocyte accumulation was noted in BAL from animals receiving
statin (P < .001, n  4).
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Reduced Cytokine Content in BAL Associated With
Statin Pretreatment
Three groups were studied: unmanipulated negative con-
trols, positive controls that underwent 90 minutes of isch-
emia followed by 4 hours of reperfusion, and statin-pre-
treated animals subjected to the same LIRI protocol. TNF-
secretion in the BAL increased from 51  2.4 pg/mL in the
negative controls to 658 63 pg/mL in the positive controls
(P  .004). This was reduced with statin pretreatment by
52% to 344  43 pg/mL (P  .013, n  4) (Figure 4).
Transcription Factor Modulation by Statin
Pretreatment
To determine additional mechanisms mediating statin’s pro-
tection in LIRI, the expression of 2 proinflammatory nuclear
transcription factors were studied. Shown in Figure 5 are
representative electrophoretic mobility shift assays detailing
the nuclear translocation of NF-B and AP-1 in controls and
injured left lungs. There is minimal nuclear NF-B and
AP-1 detected in negative control animals, whereas signif-
icant translocation of both is apparent in the animals that
underwent ischemia and 15 minutes of reperfusion. The
bands that were representative for both NF-B and AP-1
were specified using cold competition with nonlabeled oli-
gonucleotide (not shown). Statin-pretreated animals clearly
demonstrate decreased translocation of NF-B to the nu-
cleus at 15 minutes of reperfusion (n  4).
Effect of Statin Treatment on eNOS and iNOS
The expression of eNOS protein was studied by Western
blot in negative controls, positive controls, and injured
animals pretreated with statin. Samples from positive con-
trols and statin-treated groups were obtained after 90 min-
utes of ischemia and 15 minutes or 4 hours of reperfusion.
Representative membranes are illustrated in Figure 6. Un-
manipulated nontreated and statin-treated animals both
demonstrated modest eNOS expression. After ischemia and
15 minutes of reperfusion, there was an increase in eNOS
expression in both groups. Although eNOS expression is
reduced at 4 hours of reperfusion in positive controls, statin-
treated animals demonstrated preserved and even increased
expression of eNOS protein (n  4). Additional Western
blots for iNOS demonstrated that ischemia-reperfusion did
not alter baseline expression (data not shown). This was true
in both control and statin-treated groups.
Effect of Statin Pretreatment on NADPH Oxidase
Activity
In addition to modulating eNOS activity, another potential
mechanism of protection of statins in reperfusion injury is
believed to be the inhibition of NADPH oxidase expression,
which would reduce the generation of free radicals. We
therefore assayed for enzyme oxidases in frozen sections of
injured lungs exposed to 90 minutes of ischemia followed
by 15 minutes of reperfusion. There is a marked increase in
staining in injured lungs (Figure 7, B) when compared with
unmanipulated negative controls (Figure 7, A). However, in
statin-treated animals there is a marked reduction in staining
(Figure 7, C). Enzyme electrophoresis performed for
NADPH oxidase showed marked expression at 15 minutes
of reperfusion. This band disappears completely in statin-
pretreated animals undergoing reperfusion of 15 minutes
(Figure 8). This indicates that the reduction in positive
staining seen in the histochemistry is probably caused by
early inhibition of NADPH oxidase associated with statin
pretreatment.
Discussion
The pleiotropic effects of statins seem to result from the
inhibition of cholesterol’s precursor mevalonic acid, which
is critical to the isoprenylation of diverse group of pro-
teins.17 Two functionally distinct pathways of prenylation
covalently attach a lipid (geranylgeranyl or farnesyl) to
different groups of membrane-associated proteins, allowing
their localization to discrete subcellular locations. Examples
of this are the Ras and Rho guanosine triphosphate (GTP)-
binding proteins. In endothelial cells, Ras translocation is
dependent on farnesylation, whereas Rho requires gera-
nylgeranylation.18 The active forms (GTP-Rho/Ras) interact
with specific kinases to activate downstream targets. Statins
inhibit both types of prenylation, leading to the inactivation
of Rho and Ras in the cytoplasm. The inactive cytosolic
forms (guanosine diphosphate-Rho/Ras) cycle with the ac-
tive membrane bound GTP-Rho/Ras.
In vitro studies of reperfusion injury indicate that the
increase in eNOS expression seen with statin pretreatment is
reversed by the addition of farnesyl but not geranyl donors.
Figure 3. Reversal of statin protection with NG-nitro-L-arginine
methyl ester (L-NAME). There was no significant difference in
lung vascular permeability between untreated animals and ani-
mals treated with L-NAME after 4 hours of reperfusion. The
decrease in permeability associated with statin treatment was
reversed with concurrent L-NAME administration (P < .03).
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Although such reversal is not pharmacologically possible in
vivo, Rho inhibition of Clostridium botulinum C3 trans-
ferase promotes eNOS up-regulation in endothelial cells.19
Therefore, statin-induced up-regulation of eNOS expression
is believed to occur by an inhibition of the Rho GTPase
protein. The observed pattern of eNOS up-regulation with
hypoxia and gradual diminution with ensuing reperfusion is
in agreement with other in vivo studies.4,7,9 Blockade of
eNOS was shown to worsen late, but not early, reperfusion
injury, indicating that eNOS activity is protective against
late reperfusion injury. Therefore, in the present study, the
persistence of eNOS protein at 4 hours of reperfusion in
statin-treated animals likely explains the reduction in late
tissue injury and neutrophil accumulation. This hypothesis
Figure 4. Enzyme-linked immunosorbent assay for tumor necrosis factor (TNF)- content of lavage fluid. There was
a marked increase in TNF- content in lavage fluid from left lungs at 4 hours of reperfusion. Statin-treated animals
demonstrated a significant reduction of TNF- when compared with positive controls (P < .013; n  4).
Figure 5. Electrophoretic mobility shift assay for nuclear factor (NF)-B and activator protein (AP)-1. The first 2
columns represent unmanipulated negative controls. The middle 2 columns are positive controls subjected to
ischemia and 15 minutes of reperfusion. The final 2 columns reveal a marked reduction in nuclear translocation
of NF-B and AP-1 in animals treated with simvastatin (n  4).
Figure 6. Western blot for endothelial nitric oxide synthase (eNOS) expression. eNOS protein, with ischemia and
15 minutes of reperfusion, is increased above baseline in both treated and nontreated groups. Conversely, eNOS
expression persists only in the statin-treated group at 4 hours of reperfusion.
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is supported by the fact that the protective effects of statins
in late (4 hours) reperfusion are reversed by the adminis-
tration of the eNOS and iNOS antagonist L-NAME.
Another potential mechanism mediating the protective
effects of statins may involve inhibition of free radical
production.20-22 In vitro, the reduction in production of
ROIs seen after statin treatment is associated with inhibition
of NAPDH oxidase activity in macrophages12 and endothe-
lial cells.13 In this study, we demonstrated that after treat-
ment with statins, the expression of NADPH oxidase is
inhibited, which would result in a decrease in mitochondrial
ROI production. Not only do ROIs have direct toxic effects,
they also stimulate the transcription factors NF-B and
AP-1.23 These transcription factors, once activated, promote
the transcription of a number of cytokines, chemokines, and
adhesion molecules that potentiate tissue injury by neutro-
phil recruitment and endothelial damage.24 Therefore, statin
inhibition of free-radical production has widespread effects
on the proinflammatory cascade.
In the field of lung transplantation, the ability to pretreat
donors or recipients with a currently used, readily available
drug makes the potential use of statins very promising.
Further studies using an orthotopic transplant model will
likely delineate other potential benefits from their adminis-
tration to either the donor or recipient. Furthermore, the
availability of parenteral formulations of statins (which
could be added to lung preservative solutions) may allow
for the development of novel protective strategies.
Figure 7. Nicotinamide adenine dinucleotide phosphate (NADPH) diaphorase stain. Statin treatment reduces
NADPH-dependent oxidase activity in left lungs at 15 minutes of reperfusion when compared with nontreated
controls. Frozen sections stained are as follows. A, Normal left lung (200). B, Nontreated left lungs subjected to
ischemia and 15 minutes of reperfusion (200). C, Simvastatin pretreatment followed by ischemia and 15 minutes
of reperfusion (200).
Figure 8. Characterization of NADPH oxidase activity. Nondenaturing electrophoresis of whole lung protein
lysates were performed on 6% polyacrylamide gels. Gels were stained for enzyme activity using a modified
diaphorase. A, Prestained standard. Myosin (200 kDa) and -galactosidase (133 kDa). B, Unmanipulated lungs. C,
Lungs from statin-treated unmanipulated animals. D, Animals subjected to ischemia and 15 minutes of reperfusion.
Contains a single band (calculated molecular weight 253 kDa) that correlates to intact NADPH oxidase (molecular
weight 267 kDa). E, Statin-treated animals subjected to ischemia and 15 minutes of reperfusion. Statin pretreatment
resulted in a dramatic reduction in NADPH oxidase activity.
Cardiothoracic Transplantation Naidu et al
488 The Journal of Thoracic and Cardiovascular Surgery ● August 2003
TX
Summary
This study has shown that pretreatment with simvastatin is
protective against lung reperfusion injury in a rodent model.
The likely mechanisms of protection include altered free
radical generation through effects on NADPH oxidase and
preservation of endogenous NO activity.
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